ELDN
Eledon Pharmaceuticals Inc
2.70$
+2.7%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -36.9% | -56.2% | -29.8% | -18.5% | -35.8% | +1,703.9% | -13.5% | -45.6% | +35.7% | +40.9% | -4.7% | |
| – | -37.5% | -56.0% | -35.7% | -24.9% | -30.2% | +1,059.7% | -23.6% | -32.6% | -5.7% | +156.1% | -5.6% | |
| – | -77.2% | -3.3% | -25.8% | -24.7% | -32.2% | +1,199.0% | -25.7% | -33.5% | -91.8% | +345.6% | +11.0% | |
| – | -39.2% | -57.2% | -37.1% | -24.7% | -32.2% | +1,199.0% | -25.7% | -33.5% | -9.4% | +174.3% | -4.9% | |
| – | – | – | – | – | -58.8% | -55.1% | – | – | – | – | – | |
| – | – | – | – | – | – | +46.1% | – | – | – | – | – | |
| – | – | – | -19.4% | -44.0% | +2,192.9% | -57.0% | +456.5% | – | – | – | – | |
| – | – | – | – | +0.0% | -100.0% | – | +0.0% | -100.0% | – | – | – | |
| – | – | – | – | – | – | – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +47.3% | -53.6% | -50.4% | +76.0% | -42.1% | +349.5% | -0.5% | +31.4% | +393.3% | +39.5% | +48.4% | |
| – | +45.2% | -54.3% | -48.9% | +76.0% | -47.8% | +87.8% | +77.2% | +47.1% | -39.8% | +197.2% | +58.5% | |
| – | – | – | – | – | – | -20.0% | +156.3% | -1.6% | +5.5% | -18.0% | +14.0% | |
| – | +57.9% | -72.0% | +23.7% | +64.8% | -52.2% | +315.2% | +32.7% | +21.3% | -56.0% | +503.2% | -37.8% | |
| – | -40.4% | -56.5% | -27.6% | -25.5% | -34.7% | +1,913.7% | -14.0% | -48.7% | -0.9% | +41.6% | -31.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +247.6% | +66.3% | +12.6% | +92.5% | +31.0% | +28.5% | -2.2% | -3.6% | +72.3% | +97.2% | +68.6% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.